Use of dofetilide in adult patients with atrial arrhythmias and congenital heart disease: A PACES collaborative study

Dofetilide remains a viable antiarrhythmic drug option in this challenging population. At 3 years, 49% remained on dofetilide. Close monitoring of renal function, concomitant medications, and corrected QT interval is required.